Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
investigational drug
alkylphospholipid |
| gptkbp:administeredBy |
oral
|
| gptkbp:CASNumber |
157716-52-4
|
| gptkbp:clinicalTrialPhase |
Phase III (as of 2012)
|
| gptkbp:compatibleWith |
FDA (as of 2023)
|
| gptkbp:developedBy |
gptkb:cancer
|
| gptkbp:discoveredBy |
gptkb:Keryx_Biopharmaceuticals
|
| gptkbp:hasInChIKey |
JYJXKQIEEJQXQH-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
C37H74NO4P
|
| gptkbp:hasSMILES |
CCCCCCCCCCCCCCCCCN1CCC(CC1)(C)COP(=O)(O)O
|
| gptkbp:hasUNII |
8VZV102F5A
|
| https://www.w3.org/2000/01/rdf-schema#label |
Perifosine
|
| gptkbp:investigatedBy |
colorectal cancer
multiple myeloma solid tumors |
| gptkbp:mechanismOfAction |
Akt pathway inhibitor
|
| gptkbp:molecularWeight |
628.96 g/mol
|
| gptkbp:PubChem_CID |
9941372
CHEMBL1201732 DB06446 |
| gptkbp:sideEffect |
nausea
diarrhea fatigue gastrointestinal toxicity |
| gptkbp:synonym |
gptkb:KRX-0401
gptkb:octadecyl-(1,1-dimethyl-piperidinio-4-yl)-phosphate |
| gptkbp:target |
gptkb:Akt
PI3K/Akt pathway |
| gptkbp:bfsParent |
gptkb:AKT
|
| gptkbp:bfsLayer |
6
|